FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024362267> ?p ?o ?g. }

• W2024362267 endingPage "434" @default.
• W2024362267 startingPage "429" @default.
• W2024362267 abstract "Courses of antituberculous chemotherapy are more prolonged than ever, and the problem of the unpleasant side effects of the administration of para-aminosalicylic acid (PAS) harasses both patient and physician for longer periods of time. Clinicians who manage tuberculosis are quite familiar with the difficulties entailed in keeping an appreciable number of their patients on an uninterrupted, prolonged course of para-aminosalicylic acid. In my experience, at least 25 per cent of patients receiving this antituberculous drug develop anorexia, epigastric distress, nausea, vomiting, abdominal cramps, or diarrhea. Quite an appreciable number discontinue the medication on their own or have it discontinued by the physician because of these symptoms. Many others who continue the drug despite these unpleasant symptoms, have the extra burden of side effects added to the already heavy burden of tuberculosis, with its physical, social, economic and emotional difficulties. The physician is faced with the problem of finding either a form of the drug that will be tolerated or an adjuvant that will help control the unpleasant symptoms. Among the variations of the drug used are buffered tablets, granules, coated tablets, and salts of the acid. Recently, potassium para-aminosalicylate has been recommended for use in place of other para-aminosalicylic acid preparations, as carrying a high degree of patient tolerance and acceptance.’ Many different medicaments have been employed as adjuvants with varied degrees of success in an attempt to control the unpleasant side effects. Among them are the antacids, tincture of belladonna, other antispasmodics, camphorated tincture of opium, and dramamine.#{174}2 The effectiveness of chlorpromazine in the control of drug induced nausea and vomiting is well known.3’ � � It is the purpose of this paper to present the results of the use of this versatile drug in the control of side-effects of oral administration of para-aminosalicylic acid in the treatment of pulmonary tuberculosis. Material A total of 91 patients (87 males and four females) who experienced side effects attributable to para-aminosalicylic acid during courses of chemotherapy, and were treated with chlorpromazine are included in this study. They ranged from 21 to 63 years of age, with an average of 39. Both hospitalized and ambulatory patients are included. Those hospitalized were" @default.
• W2024362267 created "2016-06-24" @default.
• W2024362267 creator A5064305888 @default.
• W2024362267 date "1956-10-01" @default.
• W2024362267 modified "2023-10-05" @default.
• W2024362267 title "Chlorpromazine in the Control of Side Effects of Para-Aminosalicylic Acid Administration" @default.
• W2024362267 cites W1988768278 @default.
• W2024362267 cites W2041174522 @default.
• W2024362267 cites W2049583368 @default.
• W2024362267 cites W2056125123 @default.
• W2024362267 doi "https://doi.org/10.1378/chest.30.4.429" @default.
• W2024362267 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/13365490" @default.
• W2024362267 hasPublicationYear "1956" @default.
• W2024362267 type Work @default.
• W2024362267 sameAs 2024362267 @default.
• W2024362267 citedByCount "1" @default.
• W2024362267 crossrefType "journal-article" @default.
• W2024362267 hasAuthorship W2024362267A5064305888 @default.
• W2024362267 hasConcept C17744445 @default.
• W2024362267 hasConcept C185592680 @default.
• W2024362267 hasConcept C199539241 @default.
• W2024362267 hasConcept C2775843808 @default.
• W2024362267 hasConcept C2776206795 @default.
• W2024362267 hasConcept C2778775820 @default.
• W2024362267 hasConcept C2780765947 @default.
• W2024362267 hasConcept C2909441351 @default.
• W2024362267 hasConcept C501593827 @default.
• W2024362267 hasConcept C55493867 @default.
• W2024362267 hasConcept C71924100 @default.
• W2024362267 hasConcept C98274493 @default.
• W2024362267 hasConceptScore W2024362267C17744445 @default.
• W2024362267 hasConceptScore W2024362267C185592680 @default.
• W2024362267 hasConceptScore W2024362267C199539241 @default.
• W2024362267 hasConceptScore W2024362267C2775843808 @default.
• W2024362267 hasConceptScore W2024362267C2776206795 @default.
• W2024362267 hasConceptScore W2024362267C2778775820 @default.
• W2024362267 hasConceptScore W2024362267C2780765947 @default.
• W2024362267 hasConceptScore W2024362267C2909441351 @default.
• W2024362267 hasConceptScore W2024362267C501593827 @default.
• W2024362267 hasConceptScore W2024362267C55493867 @default.
• W2024362267 hasConceptScore W2024362267C71924100 @default.
• W2024362267 hasConceptScore W2024362267C98274493 @default.
• W2024362267 hasIssue "4" @default.
• W2024362267 hasLocation W20243622671 @default.
• W2024362267 hasLocation W20243622672 @default.
• W2024362267 hasOpenAccess W2024362267 @default.
• W2024362267 hasPrimaryLocation W20243622671 @default.
• W2024362267 hasRelatedWork W1516644182 @default.
• W2024362267 hasRelatedWork W2024362267 @default.
• W2024362267 hasRelatedWork W2246394181 @default.
• W2024362267 hasRelatedWork W2267959400 @default.
• W2024362267 hasRelatedWork W2268519552 @default.
• W2024362267 hasRelatedWork W2411692365 @default.
• W2024362267 hasRelatedWork W2426962191 @default.
• W2024362267 hasRelatedWork W2462801750 @default.
• W2024362267 hasRelatedWork W2748952813 @default.
• W2024362267 hasRelatedWork W2899084033 @default.
• W2024362267 hasVolume "30" @default.
• W2024362267 isParatext "false" @default.
• W2024362267 isRetracted "false" @default.
• W2024362267 magId "2024362267" @default.
• W2024362267 workType "article" @default.